idelalisib + bendamustine

**Idelalisib + bendamustine** is a combination therapy of two antineoplastic agents used primarily in hematological malignancies, especially chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)[1][3][4].\n- **Idelalisib** is a highly selective small molecule inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase delta (PI3Kδ), principally expressed in leukocytes. It induces apoptosis and disrupts cancer cell proliferation and survival, targeting key B-cell receptor (BCR) signaling pathways[2][6].\n- **Bendamustine** is an alkylating agent that induces DNA damage leading to cell death in susceptible lymphoid malignancies.\nThe combination is synergistic, with idelalisib potentiating bendamustine's ability to damage DNA and suppressing microenvironment-mediated resistance in CLL. Mechanistically, it enhances DNA damage responses (phosphorylation of ATM, Chk2, and p53), apoptosis, and disrupts survival signaling regulated by PI3K/Akt[1].\nBoth are approved individually for CLL; however, the combination has been investigated in Phase 1 and Phase 3 trials for relapsed/refractory iNHL and CLL. Increased toxicity in some populations led to early termination of certain Phase 3 studies[3][4][5].

Other names

idelalisib + bendamustine